[Randomized placebo trial of myeloprotection with goralatide in patients with squamous cell carcinoma of the upper respiratory and digestive tracts or esophagus, treated with a carboplatin-fluorouracil combination].

P Cappelaere(European Organisation for Research and Treatment of Cancer), Patrice Carde(Institut Gustave Roussy), I. Krakowski, C. Domenge(Institut Gustave Roussy), De Gislain C, J Chauvergne(European Organisation for Research and Treatment of Cancer), L Méeus, F. Dufour-Esquerré, F. Rolland(Institut de Cancérologie de l'Ouest), B Hecquet(Institut für Gießereitechnik)

PubMed

September 1, 1995

Cited by 4

Related Papers

p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies

|Blood|1994|581

Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma

|British Journal of Cancer|2000|253

Eight Cycles of ABVD Versus Four Cycles of BEACOPP<sub>escalated</sub>Plus Four Cycles of BEACOPP<sub>baseline</sub>in Stage III to IV, International Prognostic Score ≥ 3, High-Risk Hodgkin Lymphoma: First Results of the Phase III EORTC 20012 Intergroup Trial

|Journal of Clinical Oncology|2016|121

Clinical impact of pharmacokinetically-guided dose adaptation of 5-fluorouracil: results from a multicentric randomized trial in patients with locally advanced head and neck carcinomas.

|PubMed|1998|114

LBA35 Avelumab-cetuximab-radiotherapy versus standards of care in patients with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): Randomized phase III GORTEC-REACH trial

|Annals of Oncology|2021|87